Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta blockers in post-infarction state].

Heinz-Peter Schultheiss1, Carsten Tschöpe

  • 1Abteilung für Kardiologie und Pulmologie, Medizinische Klinik II, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin. schultheiss@medizin.fu-berlin.de

Herz
|September 17, 2002
PubMed
Summary

Beta blockers, like carvedilol, are beneficial after myocardial infarction (MI), especially with heart failure. The CAPRICORN trial confirmed carvedilol reduces mortality in post-MI patients on modern therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same author

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging.

Expert review of cardiovascular therapy·2026
Same author

Highlights from the 2025 annual meeting of the ESC Working Group on Myocardial & Pericardial Diseases.

European heart journal·2026
Same author

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

European journal of heart failure·2026
Same author

Sex-Dependent Fibroblast Signatures in Heart Failure: Toward Stratified Anti-Fibro-Inflammatory Therapies.

ESC heart failure·2026
Same author

Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases.

European journal of heart failure·2026

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Randomized trials in the 1980s demonstrated the benefits of beta blockers post-myocardial infarction (MI).
  • Beta blocker use post-MI has declined, lagging behind other therapies like angiotensin-converting enzyme inhibitors (ACEIs).
  • Advances in MI management necessitate re-evaluation of beta blocker therapy, particularly in post-MI heart failure.

Purpose of the Study:

  • To evaluate the efficacy of carvedilol in patients with post-MI left ventricular dysfunction.
  • To determine if carvedilol, added to modern post-MI therapies, reduces mortality.

Main Methods:

  • The CAPRICORN trial investigated carvedilol in patients following myocardial infarction with left ventricular dysfunction.
  • This study assessed outcomes on top of contemporary post-MI treatments.

Related Experiment Videos

Main Results:

  • The CAPRICORN trial demonstrated that carvedilol treatment post-MI reduces mortality.
  • This benefit was observed in patients receiving standard modern post-MI therapies.

Conclusions:

  • Carvedilol is effective in reducing mortality in post-MI patients with left ventricular dysfunction.
  • Further research is needed to confirm if other beta blockers offer similar benefits.